{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Natera, Inc. Hits New 52-Week High of $200.76, Showcasing Strong Growth
Natera, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year, outpacing broader market growth. Despite operating at a loss, the company maintains a substantial market capitalization and unique financial metrics, highlighting its notable presence in the pharmaceuticals and biotechnology sector.
Natera, Inc. Hits New 52-Week High of $199.21, Up 78.16%
Natera, Inc. has achieved a new 52-week high, reflecting its strong performance with a significant increase over the past year. The company, with a market capitalization of approximately USD 22,974 million, operates in a competitive biotechnology sector, attracting attention despite its loss-making status and notable financial metrics.
Natera, Inc. Hits New 52-Week High of $198.99, Surging 72.41%
Natera, Inc. has achieved a new 52-week high, reflecting its strong performance with a significant increase over the past year. The company, with a market capitalization of approximately USD 22,974 million, operates in a competitive biotechnology sector, despite currently facing losses and a unique capital structure.
Natera, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Natera, Inc. has recently revised its evaluation amid changing market conditions, with its stock price rising to $170.38. Over the past year, it has achieved a 31.22% return, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish short-term momentum and cautious monthly trends.
Is Natera, Inc. technically bullish or bearish?
As of October 3, 2025, Natera, Inc. shows a mildly bullish trend with strong weekly indicators and solid performance, having outperformed the S&P 500 over the past year and three years, despite mixed signals from different time frames.
Natera, Inc. Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
Natera, Inc. has recently achieved a Golden Cross, indicating potential upward momentum in its stock. The company has outperformed the S&P 500, with a notable annual performance. Despite mixed technical signals, the overall sentiment suggests growing investor interest, reflecting Natera's strong position in the biotechnology sector.
Is Natera, Inc. technically bullish or bearish?
As of October 3, 2025, Natera, Inc. shows a mildly bullish technical trend with strong weekly indicators, despite some mixed monthly signals, and has outperformed the S&P 500 over the past year and three years.
Is Natera, Inc. technically bullish or bearish?
As of October 3, 2025, Natera, Inc. shows a mildly bullish trend with strong weekly indicators, despite mixed signals from longer time frames, and has outperformed the S&P 500 significantly over the past year and three years.
Natera, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Natera, Inc. has recently revised its evaluation amid changing market conditions, with its stock priced at $162.97. Over the past year, it has achieved a 31.59% return, significantly surpassing the S&P 500. The company has demonstrated strong long-term performance, with a 283.01% return over three years.
Is Natera, Inc. technically bullish or bearish?
As of September 26, 2025, Natera, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 recently but outperforming it over the past year.
Is Natera, Inc. technically bullish or bearish?
As of September 26, 2025, Natera, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 recently but outperforming it over the past year.
Is Natera, Inc. technically bullish or bearish?
As of September 26, 2025, Natera, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 recently but outperforming it over the longer term.
Natera, Inc. Stock Hits Day Low Amid Price Pressure at $163.65
Natera, Inc. faced a significant decline on September 24, 2025, reaching an intraday low. Despite this, the company has shown strong long-term performance, with substantial gains over the past year and three years. However, it faces challenges with negative EBITDA and a high price-to-book ratio.
Is Natera, Inc. technically bullish or bearish?
As of September 9, 2025, Natera, Inc. shows a neutral technical trend with mixed signals, including a bullish weekly MACD and mildly bearish monthly MACD, while outperforming the S&P 500 with a 1-year return of 41.51% compared to 17.14%.
Is Natera, Inc. technically bullish or bearish?
As of June 2, 2025, Natera, Inc. exhibits a bullish technical trend supported by positive MACD indicators, moving averages, and KST across weekly and monthly charts, despite some mildly bullish signals from Bollinger Bands and OBV.
Who are in the management team of Natera, Inc.?
As of March 2022, Natera, Inc.'s management team includes Dr. Matthew Rabinowitz (Executive Chairman), Mr. Steven Chapman (CEO), Mr. Jonathan Sheena (CTO), and several independent directors, including Roelof Botha and Dr. Monica Bertagnolli. This team provides strategic direction and governance for the company.
What does Natera, Inc. do?
Natera, Inc. is a mid-cap diagnostics company specializing in genetic testing services, with recent net sales of $502 million and a net loss of $67 million. The company has a market cap of approximately $22.88 billion and does not pay dividends.
How big is Natera, Inc.?
As of Jun 18, Natera, Inc. has a market capitalization of $22.88 billion, with net sales of $1.83 billion and a net profit of -$189.76 million over the last four quarters. The company reported shareholder's funds of $1.20 billion and total assets of $1.69 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
